EAGLE PHARMACEUTICALS, INC. Annual Income Tax Expense (Benefit) in USD from 2012 to 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Eagle Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2012 to 2022.
  • Eagle Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2023 was $4.13M, a 15.4% increase year-over-year.
  • Eagle Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2023 was $17.2M, a 1.96% decline year-over-year.
  • Eagle Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was $25.8M, a 532% increase from 2021.
  • Eagle Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was $4.08M, a 61.8% decline from 2020.
  • Eagle Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2020 was $10.7M, a 39.1% increase from 2019.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.